BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 14982868)

  • 21. Genomic aberrations and survival of patients with light-chain-only multiple myeloma undergoing autologous stem cell transplantation.
    Jiang N; Qi C; Trieu Y; Reece D; Chang H
    Biol Blood Marrow Transplant; 2011 Dec; 17(12):1790-5. PubMed ID: 21658460
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma.
    Chang H; Ning Y; Qi X; Yeung J; Xu W
    Br J Haematol; 2007 Oct; 139(1):51-4. PubMed ID: 17854306
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis.
    Varma A; Sui D; Milton DR; Tang G; Saini N; Hasan O; Mukherjee A; Joseph JJ; Bashir Q; Rondon G; Srour S; Popat UR; Hosing CM; Nieto Y; Kebriaei P; Alousi AM; Ahmed S; Mehta R; Khouri IF; Ahmed H; Iyer S; Weber DM; Thomas SK; Manasanch E; Lee HC; Patel K; Ciurea SO; Shpall EJ; Orlowski RZ; Champlin RE; Qazilbash MH
    Biol Blood Marrow Transplant; 2020 Apr; 26(4):665-671. PubMed ID: 31881283
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term follow up of patients with multiple myeloma after high-dose chemotherapy and allogeneic stem cell transplantation.
    Rabitsch W; Prinz E; Ackermann J; Wöhrer S; Kaufmann H; Seidl S; Keil F; Kalhs P; Greinix H; Gisslinger H; Leitner G; Drach J
    Eur J Haematol; 2004 Jan; 72(1):26-31. PubMed ID: 14962259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic Implications of Monosomies in Patients With Multiple Myeloma.
    Shin SY; Eom HS; Sohn JY; Lee H; Park B; Joo J; Jang JH; Lee MN; Kim JK; Kong SY
    Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):159-164.e2. PubMed ID: 28089441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The prognostic significance of 13q deletions of different sizes in patients with B-cell chronic lymphoproliferative disorders: a retrospective study.
    Yi S; Li H; Li Z; Xiong W; Liu H; Liu W; Lv R; Yu Z; Zou D; Xu Y; An G; Qiu L
    Int J Hematol; 2017 Sep; 106(3):418-425. PubMed ID: 28439775
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interstitial 13q14 deletions detected in the karyotype and translocations with concomitant deletion at 13q14 in chronic lymphocytic leukemia: different genetic mechanisms but equivalent poorer clinical outcome.
    Puiggros A; Venturas M; Salido M; Blanco G; Fernandez-Rodriguez C; Collado R; Valiente A; Ruiz-Xivillé N; Carrió A; Ortuño FJ; Luño E; Calasanz MJ; Ardanaz MT; Piñán MÁ; Talavera E; González MT; Ortega M; Marugán I; Ferrer A; Gimeno E; Bellosillo B; Delgado J; Hernández JÁ; Hernández-Rivas JM; Espinet B; ;
    Genes Chromosomes Cancer; 2014 Sep; 53(9):788-97. PubMed ID: 24915757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A higher percentage of cells with 13q deletion predicts worse outcome in Chinese patients with chronic lymphocytic leukemia carrying isolated 13q deletion.
    Miao Y; Miao Y; Shi K; Sun Q; Zhao SS; Xia Y; Qin SC; Qiu HR; Yang H; Xu H; Zhu HY; Wu JZ; Wu W; Cao L; Wang L; Fan L; Xu W; Li JY
    Ann Hematol; 2018 Sep; 97(9):1663-1669. PubMed ID: 29736587
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Comparison of standard prognostic factors with the deletion of 13q14 detected by interphase fluorescence in situ hybridization on separated and unseparated bone marrow cells in multiple myeloma].
    Smejkalová J; Vranová V; Oltová A; Kuglík P; Filková H; Heinigová J; Kovárová L; Adam Z; Krejcí M; Pour L; Büchler T; Svobodník A; Vostrejsová S; Kalábová V; Vorlícek J; Penka M; Hájek R
    Cas Lek Cesk; 2005; 144(7):483-8. PubMed ID: 16161543
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study.
    Oh S; Koo DH; Kwon MJ; Kim K; Suh C; Min CK; Yoon SS; Shin HJ; Jo DY; Kwak JY; Kim JS; Sohn SK; Joo YD; Eom HS; Kim SH; Kim YS; Kim C; Mun YC; Kim H; Lee DS; Lee JH;
    Ann Hematol; 2014 Aug; 93(8):1353-61. PubMed ID: 24671365
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
    Cook G; Royle KL; O'Connor S; Cairns DA; Ashcroft AJ; Williams CD; Hockaday A; Cavenagh JD; Snowden JA; Ademokun D; Tholouli E; Andrews VE; Jenner M; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Pratt G; Drayson MT; Brown JM; Morris TCM;
    Br J Haematol; 2019 May; 185(3):450-467. PubMed ID: 30729512
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma.
    Maffini E; Storer BE; Sandmaier BM; Bruno B; Sahebi F; Shizuru JA; Chauncey TR; Hari P; Lange T; Pulsipher MA; McSweeney PA; Holmberg L; Becker PS; Green DJ; Mielcarek M; Maloney DG; Storb R
    Haematologica; 2019 Feb; 104(2):380-391. PubMed ID: 30262560
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant.
    Qazilbash MH; Saliba RM; Ahmed B; Parikh G; Mendoza F; Ashraf N; Hosing C; Flosser T; Weber DM; Wang M; Couriel DR; Popat U; Kebriaei P; Alousi AM; Anderlini P; Naeem RC; Champlin RE; Giralt SA
    Biol Blood Marrow Transplant; 2007 Sep; 13(9):1066-72. PubMed ID: 17697969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Presalvage International Staging System Stage and Other Important Outcome Associations in CD34
    Bryant AR; Hilden P; Giralt S; Chung DJ; Maloy M; Landau H; Landgren O; Scordo M; Shah G; Smith EL; O'Reilly RJ; Perales MA; Koehne G
    Biol Blood Marrow Transplant; 2020 Jan; 26(1):58-65. PubMed ID: 31493537
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma.
    Kaufman GP; Gertz MA; Dispenzieri A; Lacy MQ; Buadi FK; Dingli D; Hayman SR; Kapoor P; Lust JA; Russell S; Go RS; Hwa YL; Kyle RA; Rajkumar SV; Kumar SK
    Leukemia; 2016 Mar; 30(3):633-9. PubMed ID: 26487275
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chromosome 13q deletion and IgH abnormalities may be both masked by near-tetraploidy in a high proportion of multiple myeloma patients: a combined morphology and I-FISH analysis.
    Koren-Michowitz M; Hardan I; Berghoff J; Yshoev G; Amariglio N; Rechavi G; Nagler A; Trakhtenbrot L
    Cancer Lett; 2007 Oct; 255(2):307-14. PubMed ID: 17590504
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MicroRNA-15a/16-1 cluster located at chromosome 13q14 is down-regulated but displays different expression pattern and prognostic significance in multiple myeloma.
    Li F; Xu Y; Deng S; Li Z; Zou D; Yi S; Sui W; Hao M; Qiu L
    Oncotarget; 2015 Nov; 6(35):38270-82. PubMed ID: 26516702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A high number of losses in 13q14 chromosome band is associated with a worse outcome and biological differences in patients with B-cell chronic lymphoid leukemia.
    Hernández JA; Rodríguez AE; González M; Benito R; Fontanillo C; Sandoval V; Romero M; Martín-Núñez G; de Coca AG; Fisac R; Galende J; Recio I; Ortuño F; García JL; de las Rivas J; Gutiérrez NC; San Miguel JF; Hernández JM
    Haematologica; 2009 Mar; 94(3):364-71. PubMed ID: 19252174
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II.
    Shaughnessy J; Tian E; Sawyer J; McCoy J; Tricot G; Jacobson J; Anaissie E; Zangari M; Fassas A; Muwalla F; Morris C; Barlogie B
    Br J Haematol; 2003 Jan; 120(1):44-52. PubMed ID: 12492575
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma.
    Kröger N; Schwerdtfeger R; Kiehl M; Sayer HG; Renges H; Zabelina T; Fehse B; Tögel F; Wittkowsky G; Kuse R; Zander AR
    Blood; 2002 Aug; 100(3):755-60. PubMed ID: 12130482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.